Navigation Links
Cephalon Presents Positive Results for Fentora in Breakthrough Pain,,,Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance

FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon, Inc. Phase 3 clinical trial presented today at the 59th Annual Meeting of the American Academy of Neurology in Boston highlights data demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II] is beneficial for the treatment of breakthrough pain in patients with neuropathic pain who are already taking opioids around-the clock to manage their persistent pain. This study marks the first time an opioid has been evaluated in patients with breakthrough pain associated with chronic neuropathic pain.

"This study provides strong evidence that opioids like FENTORA may be useful in managing breakthrough pain in patients with chronic neuropathic pain," said Dr. David Simpson, Professor of Neurology at Mount Sinai Medical Center and primary author of this study. "With FENTORA, patients experienced statistically significant and clinically meaningful improvements in pain control and expressed a preference for this medication over the opioid they had previously been prescribed to manage their breakthrough pain."

Breakthrough pain -- a component of chronic pain -- is a flare of moderate-to-severe pain that occurs in the context of controlled persistent pain and is characterized by rapid onset, moderate-to-severe intensity, and relatively short duration. An estimated 74 percent of patients with controlled persistent pain from noncancer chronic pain conditions, including neuropathic pain, will experience breakthrough pain with a median onset of 10 minutes. In this patient population, breakthrough pain episodes can typically last 60 minutes. FENTORA, which is approved for the management of breakthrough pain in patients with cancer who are already taking and who are tolerant to opioids for their underlying persistent cancer pain, is desig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:5/30/2015)... May 30, 2015 ... in Progression-Free Survival in the liver for patients ... line with SIR-Spheres® Y-90 resin microspheres plus chemotherapy   ... Y-90 resin microspheres to a current systemic chemotherapy ... cancer (mCRC) reported in the SIRFLOX study, were ...
(Date:5/30/2015)... Pharma Inc. (TSE: 4503) today announced that preliminary data ... and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, ... leukemia (AML) were presented during an oral abstract session ... meeting in Chicago . ... and AXL, which are involved in the growth of ...
(Date:5/30/2015)... and VANCOUVER, British Columbia , ... OGXI ) announced today that results from a ... a benefit with custirsen therapy in men with metastatic ... The analysis, exploring the effect of clusterin inhibition in ... 40 percent of men in the trial had at ...
Breaking Medicine Technology:SIRFLOX Study Presented at ASCO 2015 Annual Meeting 2SIRFLOX Study Presented at ASCO 2015 Annual Meeting 3SIRFLOX Study Presented at ASCO 2015 Annual Meeting 4SIRFLOX Study Presented at ASCO 2015 Annual Meeting 5SIRFLOX Study Presented at ASCO 2015 Annual Meeting 6SIRFLOX Study Presented at ASCO 2015 Annual Meeting 7Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 2Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6
(Date:5/30/2015)... The results of a 40+ year study ... potential to cause mesothelioma, regardless of the volume of ... the Surviving Mesothelioma website. , The study conducted ... Poland found that, among the 138 cases of mesothelioma ... all of them happened at plants that had, at ...
(Date:5/30/2015)... New York (PRWEB) May 30, 2015 ... pay $100 million in punitive and compensatory damages ... plaintiff who suffered serious complications following implantation of ... to a verdict rendered on May 28th in ... million in compensatory damages after the jury found ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... The Brain Fitness Education seminar was ... Senior Enrichment Center, headed by 1Heart Client Care Manager ... Brain Fitness Program Director Tee Barr. , Senior residents ... there are many ways to enrich and further improve ... the different ways to overcome dementia and memory loss. ...
(Date:5/30/2015)... 30, 2015 San Luis Obispo ... is offering a free analysis and consultation for anyone ... with Disability Awareness Month, which was created by the ... the United States such as Polk recognize the proclamation, ... about the possibility of disability, as well as the ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... Cord Blood America, Inc., (OTC Bulletin Board: CBAI) ( ... has selected Somerville Associates, a 25 year-old public relations ... counsel for Cord Blood America, Inc., according to Matthew ... The agency will publicize Cord Blood America in ...
... Anthem Blue Cross implemented an across-the-board increase in Californai Medicare ... senior citizens to look for new ways to maximize healthcare ... ... Los Angeles, CA (PRWEB) March 20, 2009 -- Anthem Blue ...
... Reflex Plus surgical microscope from Endure Medical, Inc. represents a new ... ... March 20, 2009 -- Endure Medical ( www.enduremed.com ) has created ... excellent optical quality, exceptional red reflex and a price that is ...
... and also have an abnormality in the heart,s electrical cycle ... than people who do not have abnormal electrical activity at ... The study also provides a threshold at which the threat ... in women and 438 milliseconds in men have the worst ...
... Silver 2009 ADDY® Award for its multi-media drug education and prevention campaign ... public service announcements. , ... Los Angeles, Ca (PRWEB) March 19, 2009 ... to 60 seconds in duration, brings home the stark reality of what ...
... 20 , - On Average a ... and Poland Claim Worsening Quality of Sleep,Thanks to the Economy(1) , ... Making the Admission, Compared,to 17% of the UK(1) , ... Problems Sleeping,Over the Last 12 Months, but Only 19% of These ...
Cached Medicine News:Health News:Cord Blood America, Inc. Appoints Somerville Associates, Public Relations Counsel 2Health News:Seniors Seek to Reduce Healthcare Costs as Anthem Blue Cross Increases Premiums 2Health News:Endure Medical Redefines Ophthalmic Surgical Microscopes 2Health News:Abnormal EKG can predict death in stroke patients 2Health News:Foundation for the Drug-Free World Honored with Seven ADDY Awards 2Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 2Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 3Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 4Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 5
... relieve low back discomfort. Strong mesh elastic ... comfortable, custom fit. Optional metal stays may ... spine. Wide elastic adjustment panels provide varying ... easily accessed and adjusted. Simple hood and ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
... Pelvic Brace is the solution to the ... off-the-shelf brace fits like a custom and ... minutes. The Bledsoe Simple Pelvic Brace limits ... and adduction in 15 increments from -30 ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: